Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS, Mok CKP, Li JKC, Chan KKP, Luk KS, Lee BHW, Gu H, Chan KCK, Tsang LCH, Yiu KYS, Ling KKC, Tang YS, Luk LLH, Yu JKM, Pekosz A, Webby RJ, Cowling BJ, Hui DSC, Peiris M. Cheng SMS, et al. Among authors: luk llh. Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9. Virol J. 2024. PMID: 38515117 Free PMC article.
Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines.
Peiris M, Cheng S, Mok CKP, Leung Y, Ng S, Chan K, Ko F, Yiu K, Lam B, Lau E, Chan K, Luk L, Li J, Tsang L, Poon L, Chen C, Hui D. Peiris M, et al. Res Sq [Preprint]. 2022 Jan 5:rs.3.rs-1207071. doi: 10.21203/rs.3.rs-1207071/v1. Res Sq. 2022. Update in: Nat Med. 2022 Mar;28(3):486-489. doi: 10.1038/s41591-022-01704-7. PMID: 35018372 Free PMC article. Updated. Preprint.
Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
Shiu EYC, Cheng SMS, Martín-Sánchez M, Au NYM, Chan KCK, Li JKC, Fung LWC, Luk LLH, Chaothai S, Kwan TC, Ip DKM, Leung GM, Poon LLM, Peiris JSM, Leung NHL, Cowling BJ. Shiu EYC, et al. Among authors: luk llh. Vaccine. 2024 Sep 13;42(26):126317. doi: 10.1016/j.vaccine.2024.126317. Online ahead of print. Vaccine. 2024. PMID: 39276621
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.
Rosa Duque JS, Cheng SMS, Cohen CA, Leung D, Wang X, Mu X, Chung Y, Lau TM, Wang M, Zhang W, Zhang Y, Wong HHW, Tsang LCH, Chaothai S, Kwan TC, Li JKC, Chan KCK, Luk LLH, Ho JCH, Li WY, Lee AMT, Lam JHY, Chan SM, Wong WHS, Tam IYS, Mori M, Valkenburg SA, Peiris M, Tu W, Lau YL. Rosa Duque JS, et al. Among authors: luk llh. World J Pediatr. 2024 Apr;20(4):353-370. doi: 10.1007/s12519-023-00764-0. Epub 2023 Dec 12. World J Pediatr. 2024. PMID: 38085470 Free PMC article. Clinical Trial.
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL, Cheng SMS, Cohen CA, Martín-Sánchez M, Au NYM, Luk LLH, Tsang LCH, Kwan KKH, Chaothai S, Fung LWC, Cheung AWL, Chan KCK, Li JKC, Ng YY, Kaewpreedee P, Jia JZ, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Valkenburg SA, Cowling BJ. Leung NHL, et al. Among authors: luk llh. Lancet Microbe. 2023 Sep;4(9):e670-e682. doi: 10.1016/S2666-5247(23)00216-1. Epub 2023 Aug 4. Lancet Microbe. 2023. PMID: 37549680 Free PMC article. Clinical Trial.
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents.
Leung D, Cohen CA, Mu X, Rosa Duque JS, Cheng SMS, Wang X, Wang M, Zhang W, Zhang Y, Tam IYS, Lam JHY, Chan SM, Chaothai S, Kwan KKH, Chan KCK, Li JKC, Luk LLH, Tsang LCH, Chu NC, Wong WHS, Mori M, Leung WH, Valkenburg S, Peiris M, Tu W, Lau YL. Leung D, et al. Among authors: luk llh. Front Immunol. 2023 Mar 6;14:1106837. doi: 10.3389/fimmu.2023.1106837. eCollection 2023. Front Immunol. 2023. PMID: 36949953 Free PMC article.
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
Mu X, Cohen CA, Leung D, Rosa Duque JS, Cheng SMS, Chung Y, Wong HHW, Lee AMT, Li WY, Tam IYS, Lam JHY, Lee DHL, Chan SM, Tsang LCH, Chan KCK, Li JKC, Luk LLH, Chaothai S, Kwan KKH, Chu NC, Mori M, Jeevan T, Kandeil A, Webby RJ, Tu W, Valkenburg SA, Peiris M, Lau YL. Mu X, et al. Among authors: luk llh. Signal Transduct Target Ther. 2022 Dec 14;7(1):397. doi: 10.1038/s41392-022-01282-7. Signal Transduct Target Ther. 2022. PMID: 36517469 Free PMC article.
Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, Hachim A, Zhang Y, Chan SM, Chaothai S, Kwan KKH, Chan KCK, Li JKC, Luk LLH, Tsang LCH, Wong WHS, Cheang CH, Hung TK, Lam JHY, Chua GT, Tso WWY, Ip P, Mori M, Kavian N, Leung WH, Valkenburg S, Peiris M, Tu W, Lau YL. Rosa Duque JS, et al. Among authors: luk llh. Nat Commun. 2022 Aug 15;13(1):4798. doi: 10.1038/s41467-022-32337-6. Nat Commun. 2022. PMID: 35970832 Free PMC article. No abstract available.
14 results